Invion Limited (ASX:IVX) agreed to acquire Next Generation Photodynamic Therapy (NGPDT) of RMW Cho Group Limited on April 6, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | 0.00% | +25.00% | 0.00% |
May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
1st Jan change | Capi. | |
---|---|---|
0.00% | 21.47M | |
+46.63% | 56.65B | |
-6.64% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.23% | 26.75B | |
-21.63% | 19.03B | |
+0.62% | 12.28B | |
+23.63% | 12.26B | |
+27.68% | 12.04B |
- Stock Market
- Equities
- IVX Stock
- News Invion Limited
- Invion Limited agreed to acquire Next Generation Photodynamic Therapy of RMW Cho Group Limited.